Is AnaptysBio Stock a Good Investment?
AnaptysBio Investment Advice | ANAB |
- Examine AnaptysBio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research AnaptysBio's leadership team and their track record. Good management can help AnaptysBio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact AnaptysBio's business and its evolving consumer preferences.
- Compare AnaptysBio's performance and market position to its competitors. Analyze how AnaptysBio is positioned in terms of product offerings, innovation, and market share.
- Check if AnaptysBio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about AnaptysBio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in AnaptysBio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if AnaptysBio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine AnaptysBio Stock
Researching AnaptysBio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 6.05. AnaptysBio had not issued any dividends in recent years.
To determine if AnaptysBio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AnaptysBio's research are outlined below:
| AnaptysBio generated a negative expected return over the last 90 days | |
| AnaptysBio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 17.16 M. Net Loss for the year was (163.62 M) with loss before overhead, payroll, taxes, and interest of (78.51 M). | |
| AnaptysBio currently holds about 442.15 M in cash with (120.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Are Medical Stocks Lagging AnaptysBio This Year |
AnaptysBio Quarterly Liabilities And Stockholders Equity |
|
AnaptysBio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AnaptysBio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AnaptysBio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact AnaptysBio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises AnaptysBio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-09 | 2021-06-30 | -0.11 | -0.02 | 0.09 | 81 | ||
2019-08-08 | 2019-06-30 | -0.99 | -0.89 | 0.1 | 10 | ||
2018-03-05 | 2017-12-31 | -0.42 | -0.3 | 0.12 | 28 | ||
2022-08-08 | 2022-06-30 | -1.02 | -1.15 | -0.13 | 12 | ||
2018-08-07 | 2018-06-30 | -0.7 | -0.57 | 0.13 | 18 | ||
2020-11-04 | 2020-09-30 | -0.72 | -0.87 | -0.15 | 20 | ||
2021-02-25 | 2020-12-31 | 1.39 | 1.2 | -0.19 | 13 | ||
2023-08-07 | 2023-06-30 | -1.7 | -1.5 | 0.2 | 11 |
Know AnaptysBio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AnaptysBio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AnaptysBio backward and forwards among themselves. AnaptysBio's institutional investor refers to the entity that pools money to purchase AnaptysBio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 465.4 K | Millennium Management Llc | 2024-06-30 | 373.8 K | 5am Venture Management, Llc | 2024-09-30 | 357.7 K | Franklin Resources Inc | 2024-09-30 | 354.4 K | Cormorant Asset Management, Llc | 2024-09-30 | 342.5 K | Federated Hermes Inc | 2024-09-30 | 317.2 K | Balyasny Asset Management Llc | 2024-09-30 | 303.2 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 300.2 K | Jennison Associates Llc | 2024-09-30 | 264.9 K | Ecor1 Capital, Llc | 2024-09-30 | 7.8 M | Fmr Inc | 2024-09-30 | 3.3 M |
AnaptysBio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 764.37 M.Market Cap |
|
AnaptysBio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (1.86) | (1.95) |
Determining AnaptysBio's profitability involves analyzing its financial statements and using various financial metrics to determine if AnaptysBio is a good buy. For example, gross profit margin measures AnaptysBio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AnaptysBio's profitability and make more informed investment decisions.
Please note, the presentation of AnaptysBio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.
Evaluate AnaptysBio's management efficiency
AnaptysBio has return on total asset (ROA) of (0.1785) % which means that it has lost $0.1785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6182) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, AnaptysBio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.5 M, whereas Total Assets are forecasted to decline to about 354.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.27 | 3.11 | |
| Tangible Book Value Per Share | 3.27 | 3.11 | |
| Enterprise Value Over EBITDA | (3.90) | (4.10) | |
| Price Book Value Ratio | 6.55 | 6.22 | |
| Enterprise Value Multiple | (3.90) | (4.10) | |
| Price Fair Value | 6.55 | 6.22 |
Evaluating the management effectiveness of AnaptysBio allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The AnaptysBio Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta (0.24) |
Basic technical analysis of AnaptysBio Stock
As of the 1st of December, AnaptysBio shows the mean deviation of 3.46, and Risk Adjusted Performance of (0.05). AnaptysBio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.AnaptysBio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AnaptysBio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AnaptysBio's Outstanding Corporate Bonds
AnaptysBio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AnaptysBio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AnaptysBio bonds can be classified according to their maturity, which is the date when AnaptysBio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand AnaptysBio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing AnaptysBio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 3.46 | |||
| Coefficient Of Variation | (1,207) | |||
| Standard Deviation | 5.26 | |||
| Variance | 27.68 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.32) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 35.57 | |||
| Value At Risk | (7.28) | |||
| Potential Upside | 5.77 | |||
| Skewness | (1.99) | |||
| Kurtosis | 10.72 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 3.46 | |||
| Coefficient Of Variation | (1,207) | |||
| Standard Deviation | 5.26 | |||
| Variance | 27.68 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.32) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 35.57 | |||
| Value At Risk | (7.28) | |||
| Potential Upside | 5.77 | |||
| Skewness | (1.99) | |||
| Kurtosis | 10.72 |
Consider AnaptysBio's intraday indicators
AnaptysBio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AnaptysBio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
AnaptysBio Corporate Filings
| 15th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
AnaptysBio Stock media impact
Far too much social signal, news, headlines, and media speculation about AnaptysBio that are available to investors today. That information is available publicly through AnaptysBio media outlets and privately through word of mouth or via AnaptysBio internal channels. However, regardless of the origin, that massive amount of AnaptysBio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AnaptysBio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AnaptysBio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AnaptysBio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AnaptysBio alpha.
AnaptysBio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards AnaptysBio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
AnaptysBio Corporate Management
| Martin Dahl | Senior Research | Profile | |
| Monique Silva | Senior Affairs | Profile | |
| James MD | Advisor | Profile | |
| Beth Mueller | Senior Resources | Profile | |
| Priya Raina | Senior Operations | Profile | |
| FAAD MBA | Chief Officer | Profile | |
| Daniel Faga | Interim Director | Profile |
Already Invested in AnaptysBio?
The danger of trading AnaptysBio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AnaptysBio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AnaptysBio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AnaptysBio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 2.086 | Quarterly Revenue Growth 8.047 | Return On Assets (0.18) | Return On Equity (1.62) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between AnaptysBio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.